Dasatinib and Quercetin in Senolytic Research
Monthly dasatinib plus quercetin treatment reduced senescence-associated gene expression in primate adipose tissue, while each compound's contribution remains unknown.
Dasatinib was studied with quercetin as a senolytic combination in nonhuman primates
Dasatinib inhibits enzymes called tyrosine kinases and is used to treat cancer. Researchers also study it with quercetin as a senolytic combination: senolytics are intended to selectively eliminate senescent cells. With monthly treatment for six months, middle-aged nonhuman primates showed reduced expression of genes associated with cellular senescence in adipose tissue.
This result concerns the two compounds used together. Marker changes alone do not establish selective elimination of senescent cells; each compound's contribution is unknown. The supplied material lacks the sample size, doses, information on control groups, and effect sizes. These data are insufficient to establish a benefit in humans.
Read next: dasatinib and senolytics
This edge gives a concrete example of drug repurposing and has a clear evidentiary boundary: the reported biomarker changes belong to the combination rather than dasatinib alone.